Comparative Pharmacology
Head-to-head clinical analysis: BANTHINE versus DARICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BANTHINE versus DARICON.
BANTHINE vs DARICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anticholinergic; competitively blocks muscarinic acetylcholine receptors, inhibiting parasympathetic impulses.
Daricon (oxyphencyclimine) is a competitive antagonist of muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses. It reduces gastrointestinal motility, gastric acid secretion, and smooth muscle spasm by blocking cholinergic activity at effector cells.
Adults: 50 mg orally four times daily, before meals and at bedtime.
5 mg orally three times daily. Maximum dose: 15 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5–3 hours in adults with normal renal function. In elderly or those with renal impairment, half-life may be prolonged to 6–8 hours, requiring dose adjustment.
Terminal elimination half-life: 12-18 hours; clinical context: allows twice-daily dosing
BANTHINE (methantheline) is primarily eliminated via renal excretion (approximately 70% unchanged) with the remainder as metabolites. Biliary/fecal elimination accounts for less than 15%. Total recovery in urine and feces is nearly complete.
Renal (70% unchanged, 30% as metabolites); biliary/fecal (10%)
Category C
Category C
Anticholinergic
Anticholinergic